- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 22.07. | Eli Lilly/Almirall's Ebglyss shows promise in atopic dermatitis patients with darker skin tones | ||
| 22.07. | Sanofi to expand respiratory vaccines pipeline with $1.6bn Vicebio acquisition | ||
| 21.07. | LEO Pharma gains access to Boehringer's skin disease drug for €90m upfront | ||
| 21.07. | AstraZeneca shares late-stage results for Tagrisso combination in lung cancer | ||
| 21.07. | EC approves SpringWorks Therapeutics' Ezmekly to treat rare genetic disorder NF1 | ||
| 18.07. | Johnson & Johnson's TAR-200 granted FDA priority review to treat bladder cancer | ||
| 18.07. | NICE recommends BeOne's Brukinsa to treat mantle cell lymphoma on NHS | ||
| 18.07. | Alnylam's Amvuttra approved by MHRA to treat rare heart disease ATTR-CM | ||
| 17.07. | Novartis' Kisqali recommended by NICE to treat broad early breast cancer population | ||
| 17.07. | MHRA approves KalVista Pharmaceuticals' Ekterly to treat hereditary angioedema attacks | ||
| 17.07. | GCI Health announces realignment of European leadership team | ||
| 16.07. | Bayer's Kerendia granted FDA approval for new heart failure indication | ||
| 16.07. | EC approves BeOne Medicines' Tevimbra to treat nasopharyngeal cancer | ||
| 16.07. | Pfizer/Astellas share positive overall survival results for Xtandi in prostate cancer | ||
| 15.07. | AstraZeneca's baxdrostat shows promise in phase 3 hypertension study | ||
| 15.07. | AbbVie gains rights to IGI's phase 1 trispecific engager in deal worth over $1.9bn | ||
| 15.07. | Vertex's triple combination cystic fibrosis therapy Alyftrek recommended by NICE | ||
| 14.07. | Merck to expand respiratory disease portfolio with $10bn Verona Pharma acquisition | ||
| 14.07. | FDA publishes over 200 complete response letters in effort to increase transparency | ||
| 11.07. | Amgen's bemarituzumab shows promise in phase 3 gastric cancer study | ||
| 11.07. | EC approves Biocon Biologics' denosumab biosimilars Vevzuo and Evfraxy | ||
| 11.07. | Current market challenges are redefining the biotech landscape | ||
| 10.07. | AstraZeneca's Imfinzi regimen approved by EC to treat muscle-invasive bladder cancer | ||
| 10.07. | FDA approves Dizal's oral therapy Zegfrovy to treat advanced lung cancer | ||
| 10.07. | Leveraging AI to supercharge early commercialisation strategy |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .